In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List

2nd Gene Therapy for Muscular Disorders

Apr 04, 2022 - 08:00 AM - Apr 07, 03:30 PM
Hanson Wade
Hyatt Regency Boston
1, Avenue

De Lafayette Boston,
ZIP: 02111
Phone: +16174554188

Ticket Price: Full Access Pass - Standard Rate: USD 4793.0, Conference + Workshop Day - Standard Rate: USD 3896.0, Conference + Post Event Vector Day - Standard Rate: USD 3896.0, Conference Only - Standard Rate: USD 2999.0

The 2nd Gene Therapy for Muscular Disorders Summit will be returning as an in-person event to Boston in April 2022, to help gene therapy developers targeting muscular disorders to overcome safety and toxicity challenges and effectively translate their programs into the clinic.

Highlighting AAV and gene editing challenges for Duchenne's (DMD), Limb-Girdle (LGMD), Pompe Disease, X-Linked Myotubular Myopathy and other muscular disorders, this industry-focused 4-day event will cover:

-Overcoming immunogenicity challenges and mitigate toxicity with high doses
-Optimizing vector and promoter choice and design for more efficient delivery tomuscle targets
-Defining clinically meaningful muscular endpoints to successfully develop and safely deliver the optimal dose to their muscular targets

Join over 150 fellow industry experts to learn, share and benchmark yourselves against your competitors, and overcome the toxicity and dosage challenges hindering the progress of your gene therapy targeting the muscle.

Group discounts and early booking rates are available. Please visit the website for full pricing information.

Brochure: https://go.evvnt.com/944879-2?pid=1052
Tickets: https://go.evvnt.com/944879-3?pid=1052

Speaker Details

Alison McVie-Wylie, Vice President, Disease Area Executive, DMD, Vertex Cell and Genetic Therapies, Anh Nguyen, Vice President, Therapeutic Sector Lead - Musculoskeletal, AskBio, Carl Morris, Chief Scientific Officer, Solid Biosciences Inc., Chris Lorenz, Senior Vice President, Technical Operations, Astellas Gene Therapies, Genine Winslow, Chief Scientific Officer, Chameleon Bioscience, Helene Haegel, Immunosafety Scientist, Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Schlieren, Roche, Jay Barth, Chief Medical Officer, Lexeo Therapeutics, Jennifer Green, Principal Scientist, R and D, Solid Biosciences, Jennifer Levy, Scientific Director Coalition to Cure, Calpain 3 (C3), Jose Trevejo, Officer and Senior Vice President of AAV, Rocket Pharmaceuticals, Joseph Rabinowitz, Joseph Rabinowitz, Kriya Therapeutics, Juan Manuel Iglesias, Director of Product R and D, Europe, Europe AskBio, Laurence Whiteley, Senior Director, Pfizer, Lianna Orlando, Senior Director of Research, CureDuchenne, Lisa Dyleski, Senior Scientist, Bioanalysi, Pfizer, Louise Rodino-Klapac, Chief Scientific Officer, Sarepta Therapeutics, Maritza McIntyre, Chief Development Officer, Stride Bio, Marla Weetall, Senior Vice President, Pharmacology and Biomarkers, PTC Therapeutics, Melissa Kotterman, Chief Scientific Officer, Iris Medicine, Olivier Danos, Chief Scientific Officer. REGENXBIO, Pat Gonzalez, Associate Director, R and D, Solid Biosciences, Perry Shieh, Professor of Neurology and Pediatrics, University of California Los Angeles and Principal Investigator for ASPIRO, Astellas Gene Therapies, Regina Espanol Suner, Scientist II, Vector Biosciences, Astellas Gene Therapies, Isabelle Richard, Chief Scientific Officer, Atamyo Therapeutics, Roger Hajjar, Therapeutic Sector Leader, Cardiac Gene Therapy, AskBio, Serge Braun, Head of Neuromuscular Strategy, Genethon, Sharif Tabebordbar, Research Scientist, Broad Institute of MIT and Harvard, Sharon Hesterlee, Chief Research Officer, Muscular Dystrophy Association, Stan Froehner, Co-Founder and Chief Executive Officer, Myosana Therapeutics, Suryanarayan Somanathan, Head of AAV Gene Therapy, Rare Disease Research Unit, Pfizer, Tudor Fulga, Vice President, Gene Editing, Vertex Cell and Genetic Therapies

Event Categories
Keywords: pharmaceutical , Medicine


Events Calendar

27 28 29 30 31 1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30


VIP Life Time Subscription to our Newsletters!